Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05340309 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Terminated to Active, Not Recruiting
    • Primary completion date: Jul 29, 2025 to Dec 31, 2026
    • Study completion date: Jul 29, 2025 to Dec 31, 2027
    v7
  2. Trial status: Recruiting to Terminated Sponsor's reason: insufficient accrualv6 Show 4 more changesShow less
    • Enrollment target: estimated 37 to confirmed 5
    • Primary completion date changed from estimate of Dec 7, 2025 to Jul 29, 2025
    • Study completion date changed from estimate of Dec 7, 2026 to Jul 29, 2025
    • Site details revised
  3. Re-verified, no change to tracked fieldsv5
  4. Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
    • Primary completion date: Dec 5, 2025 to Dec 7, 2025
    • Study completion date: Dec 5, 2026 to Dec 7, 2026
    • Start date changed from estimate of Dec 5, 2022 to Dec 7, 2022
    • Site details revised
  5. Start date: Sep 1, 2022 to Dec 5, 2022
    • Primary completion date: Sep 1, 2025 to Dec 5, 2025
    • Study completion date: Sep 1, 2026 to Dec 5, 2026
    v3
  6. Start date: May 2, 2022 to Sep 1, 2022
    • Primary completion date: May 2, 2025 to Sep 1, 2025
    • Study completion date: May 2, 2025 to Sep 1, 2026
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial tests whether subcutaneous atezolizumab can be effectively given at home with medical care provided primarily using telemedicine in patients with non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This study may help determine if a telemedicine based approach that gives atezolizumab at home using a version of the drug designed for subcutaneous injection under the skin is safe and feasible.
Trial Details
NCT Number NCT05340309
Lead Sponsor University of Southern California
Collaborators: National Cancer Institute (NCI), Genentech, Inc.
Conditions
(from sponsor)		 Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8 +3 more
Related terms Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Enrollment 5 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov